Roman Nowicki
Roman Nowicki is an expert in Dermatology at University Clinical Centre (Poland). As of October 2026, ScienceLeadR ranks Roman Nowicki in the top 1% of experts worldwide for Dermatitis, Skin Diseases, Genetic and Skin Diseases, Eczematous. Roman Nowicki has authored 330 publications, the most recent in 2026, and is an investigator in 21 clinical trials, 8 of them ongoing. SLR score: 1,411 (community average: 125). How the SLR is computed.
LeadR Profile
Dermatology
Subspecialties: Immunology - Infectiology - Biochemistry
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Short Biography
Roman J. Nowicki MD, PhD, professor in dermatology and allergology. Since 2012 he is the Head of the Department of Dermatology, Venereology, and Allergology of the Medical University of Gdansk (MUG) . He is a member of several national (Polish Dermatological Society, Polish Society of Allergology, Gdansk Science Society) and international societies (European Academy Dermatology and Venereology, European Academy of Allergology and the Clinical Immunology, Belarusian Public Organization of Dermatologists and Cosmetologists, American Academy of Dermatology - IFAAD, International Society for Human and Animal Mycology, European Nail Society and European Confederation for Medical Mycology). Since 2004 prof. Nowicki is a chairman of the Section of Dermatology Polish Society of Allergology and since 2014 chairman of the Marine Department of Polish Dermatological Society. Prof. Nowicki is an honorary Doctor of the State Medical University in Grodno (Belarus), honorary member of the Belarusian Public Organization of Dermatologists and Cosmetologists, Polish Dermatological Society and Polish Society of Allergology. He has been an organizer of the annual International Academy of Dermatology and Allergology meeting since 2004. He has also been an organizer or co-organizer for international meetings for Dermatology and Allergy without Borders (Bialowieza 2014, Grodno - Belarus 2015, 2017, Ustka 2016, Riga-Latvia 2016, Liepaja -Latvia 2018, 2022, Gdynia 2019-2024, Gdansk 2025, 26).
Organizations
Career arc: 1997 - 2026
Number : 330
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Combining Dermoscopy and Reflectance Confocal Microscopy to Improve External Ear Melanoma Diagnosis: A Multicenter Retrospective Study. PMID 42888500 — microscopy, confocal, ear, external, melanoma, hutchinson's melanotic freckle, retrospective studies, microscopy, diagnosis, wounds and injuries, dermoscopy | Int J Dermatol | 2026 | 0 |
| Ablative Fractional CO 2 Laser Therapy for a Post-Mpox Facial Scar. PMID 42858445 — cicatrix, lasers, therapeutics, laser therapy | Dermatol Pract Concept | 2026 | 0 |
| Hidradenitis Suppurativa from Preconception to Lactation: Clinical Treatment Decision-Making Review. PMID 42768237 — glucagon-like peptide 1, lactation, safety, hidradenitis suppurativa, decision making, breast feeding, hidradenitis, therapeutics | Dermatol Ther (Heidelb) | 2026 | 0 |
| A monocentric retrospective real-world study from North Poland of dupilumab in adults and paediatric patients with atopic dermatitis: efficacy, safety, and dupilumab-associated hypereosinophilia. PMID 42621421 — quality of life, safety, dermatitis, therapeutics, eosinophilia, dermatitis, atopic | Postepy Dermatol Alergol | 2026 | 0 |
| Contact Allergy to Topical Corticosteroids in Atopic Dermatitis: Diagnostic Gaps in Baseline Patch Testing. PMID 42184978 — research design, reading, petrolatum, dermatitis, hypersensitivity, adrenal cortex hormones, ethanol, propionates, clobetasol, hydrocortisone, pharmaceutical vehicles, budesonide, dermatitis, atopic, dermatitis, contact, patch tests, allergy | Contact Dermatitis | 2026 | 0 |
Clinical Studies 21
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
8 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A study to evaluate the long term safety tolerability and efficacy of subcutaneous sonelokimab in participants with moderate to severe hidradenitis suppurativa 2025-520564-17-00 — safety, hidradenitis suppurativa, hidradenitis | Phase 3 | Active not recruiting | 2025 |
| Long Term Safety and Efficacy evaluation of amlitelimab in participants of previous amlitelimab moderate to severe atopic dermatitis clinical trials 2023-506548-18-00 — safety, dermatitis, dermatitis, atopic | Phase 2/Phase 3 | Not yet recruiting | 2022 |
| A clinical trial to provide continued access to remibrutinib (LOU064) for people who are benefiting from it in a previous remibrutinib trial 2025-524078-40-00 — urticaria, multiple chronic conditions, therapeutics | Phase 3 | Recruiting | 2026 |
| A Phase 3 study to assess efficacy safety and tolerability of remibrutinib in adult and adolescent patients with moderate to severe hidradenitis suppurativa 2024-513282-39-00 — safety, hidradenitis suppurativa, hidradenitis, adolescent, therapeutics | Phase 3 | Active not recruiting | 2025 |
| Selective Treatment of Oral Povorcitinib in Prurigo Nodularis Study 1 (STOP PN1) 2024-511879-16-00 — safety, prurigo, therapeutics | Phase 3 | Active not recruiting | 2024 |
LeadR Networks
Main global connection map